Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

38
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
38
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

11
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
11
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications01:25

Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications

26
Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...
26
Peritoneal Dialysis I: Introduction and Procedure01:30

Peritoneal Dialysis I: Introduction and Procedure

37
Peritoneal dialysis (PD) is a procedure that facilitates the exchange of solutes, waste products, electrolytes, and excess fluid between the blood in the peritoneal capillaries and a dialysis solution introduced into the peritoneal cavity.Principles of Peritoneal Dialysis (PD)Diffusion: Waste products such as urea and electrolytes move from high concentrations in the blood to low concentrations in the dialysate across the peritoneal membrane. This mechanism is driven by the concentration...
37
Drug Elimination by Renal Route: Tubular Secretion01:15

Drug Elimination by Renal Route: Tubular Secretion

2.4K
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
2.4K
Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

195
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
195

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preserving Peritoneal Membrane Performance.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Reevaluating the 2.5 total-to-ionized calcium threshold during RCA-CKRT.

Critical care (London, England)·2026
Same author

Thyroid Function with Continuous KRT: A Prospective Study.

Kidney360·2026
Same author

Plasma metabolomics analysis in murine prerenal azotemia reveals changes in energy substrates, amino acid metabolism, and uremic toxins.

American journal of physiology. Renal physiology·2026
Same author

Coronary Artery Bypass Graft as a Bridge to Kidney Transplantation.

The Journal of surgical research·2026
Same author

Blood Pressure Control and Mortality Among US Veterans.

Hypertension (Dallas, Tex. : 1979)·2026

Related Experiment Video

Updated: Jul 11, 2025

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
07:11

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis

Published on: July 19, 2018

15.3K

Hepcidin Removal during Continuous Renal Replacement Therapy.

James F Colbert1,2, Benjamin R Griffin3, Kristy Rolloff4

  • 1Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA, james.colbert@cuanschutz.edu.

Blood Purification
|November 5, 2023
PubMed
Summary

Continuous renal replacement therapy (CRRT) significantly reduces hepcidin levels in patients with acute kidney injury (AKI) or end stage kidney disease (ESKD) within two days. This finding suggests CRRT may impact iron homeostasis and pathogen defense, warranting further clinical investigation.

Keywords:
Continuous renal replacement therapyHepcidinSepsis

More Related Videos

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
06:27

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

Published on: July 20, 2022

2.6K
Re-Arterialized Rat Partial Liver Transplantation with an in vivo Vessel-Oriented 70% Hepatectomy
14:52

Re-Arterialized Rat Partial Liver Transplantation with an in vivo Vessel-Oriented 70% Hepatectomy

Published on: April 8, 2018

11.7K

Related Experiment Videos

Last Updated: Jul 11, 2025

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
07:11

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis

Published on: July 19, 2018

15.3K
A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
06:27

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

Published on: July 20, 2022

2.6K
Re-Arterialized Rat Partial Liver Transplantation with an in vivo Vessel-Oriented 70% Hepatectomy
14:52

Re-Arterialized Rat Partial Liver Transplantation with an in vivo Vessel-Oriented 70% Hepatectomy

Published on: April 8, 2018

11.7K

Area of Science:

  • Nephrology
  • Critical Care Medicine
  • Immunology

Background:

  • Continuous renal replacement therapy (CRRT) is essential for managing acute kidney injury (AKI) and end-stage kidney disease (ESKD).
  • CRRT's broad solute removal may inadvertently deplete beneficial substances like hepcidin, an antimicrobial peptide crucial for iron homeostasis and pathogen defense.

Purpose of the Study:

  • To investigate the effect of CRRT initiation on serum hepcidin levels in patients with AKI or ESKD.
  • To determine if CRRT significantly alters hepcidin concentrations during treatment.

Main Methods:

  • A prospective, observational study involving 13 patients requiring CRRT (11 with AKI, 2 with ESKD).
  • Plasma and effluent samples were collected over 3 days post-CRRT initiation.
  • Hepcidin concentrations were measured and compared to healthy controls; the hepcidin sieving coefficient was calculated.

Main Results:

  • Patients initiating CRRT had significantly higher baseline hepcidin levels compared to healthy controls (158 ± 60 vs. 17 ± 3 ng/mL).
  • Hepcidin levels decreased significantly by day 1 (102 ± 24 ng/mL) and day 2 (56 ± 14 ng/mL) of CRRT, stabilizing by day 3 (51 ± 11 ng/mL).
  • The median hepcidin sieving coefficient was consistently high (0.82-0.83), indicating efficient removal by CRRT.

Conclusions:

  • CRRT initiation leads to a rapid and significant reduction in plasma hepcidin levels within the first two days of treatment.
  • This reduction occurs irrespective of the reason for CRRT or the presence of underlying ESKD.
  • Given the association of low hepcidin with increased mortality, further clinical studies are needed to explore the impact of CRRT-induced hepcidin removal on patient outcomes.